IMR Press / FBL / Volume 8 / Issue 4 / DOI: 10.2741/955

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Reticuloendotheliosis viruses and derived vectors for human gene therapy
Show Less
1 Thomas Jefferson University, Division of Infectious Diseases, 1020 Locust Street, Suite 329, Philadelphia, PA 19107, USA

Academic Editors: Roger Pomerantz, Ralph Dornburg

Front. Biosci. (Landmark Ed) 2003, 8(4), 801–817; https://doi.org/10.2741/955
Published: 1 May 2003
(This article belongs to the Special Issue Engineered retroviruses)
Abstract

The reticuloendotheliosis viruses (REV) spleen necrosis virus (SNV) and reticuloendotheliosis virus strain-A (REV-A) are amphotropic retroviruses which infect a large variety of cells of avian and some mammalian species. They normally do not infect primate or rodent cells. However, they efficiently infect and integrate their genome into that of human cells when they are pseudotyped with the envelope protein of other mammalian retroviruses or the G protein of vesicular stomatitis virus (VSV) or rabies viruses (RV). Moreover, SNV-derived retroviral vectors, which display single chain antibodies or other targeting ligands on the viral surface enable cell-type-specific gene delivery into various human cells. My laboratory has developed genetically engineered REV vectors, which are capable of infecting non-dividing cells such as quiescent human T-cells, primary monocyte-derived macrophages, and mature neurons. Thus, REV-derived vectors appear to be very interesting candidates for the further development of vectors for human gene therapy. This article reviews the replication of REVs and vectors derived from REV-A and SNV for gene transfer into human cells.

Share
Back to top